Search
Call for Proposals: 2024 Police, Treatment, and Community Collaborative (PTACC) International Deflection and Pre-arrest Diversion Summit
Proposals are now being accepted for the 2024 Police, Treatment, and Community Collaborative (PTACC) International Deflection and Pre-arrest Diversion Summit. All submissions must be uploaded by April 19, 2024 at 12:00 PM PDT in order to be...
Residential addiction treatment for adolescents is scarce and expensive
Science of Self-Care: How It Helps and Why It Matters
Synthetic Opioids: Navigating a Changing Landscape in the Treatment of Opioid Use Disorder
Alarming Statistics: Over One Million Young Drivers Imperil Lives with Marijuana and Alcohol Behind the Wheel
Driving under the influence (DUI) of psychoactive substances is an issue of paramount concern in both public health and the criminal justice system. It affects millions of Americans yearly, and while there is extensive research on DUI among...
Substance Use Disorders (SUD) and Type 2 Diabetes: Integration of Evidence-Based Diabetes Care to Promote Quality Health Outcomes
Conectando Comunidades a Serviços de Uso de Substâncias: Abordagens Práticas para Socorristas
Abstrair
Durante seu trabalho diário, os socorristas, como policiais, bombeiros e pessoal dos serviços médicos de emergência (EMS), muitas vezes encontram pessoas que usam drogas (PWUD), incluindo álcool, opioides, estimulantes e outras...
El fentanilo, información de NIDA
El fentanilo es un fuerte opioide sintético similar a la morfina, pero entre 50 y 100 veces más potente. Es un fármaco recetado que a veces también se usa en forma ilegal. Al igual que la morfina, por lo general se receta a pacientes con...
Fentanyl DrugFacts
Fentanyl is a powerful synthetic opioid that is similar to morphine but is 50 to 100 times more potent. It is a prescription drug that is also made and used illegally. Like morphine, it is a medicine that is typically used to treat patients...
FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder
For Immediate Release: May 23, 2023
Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD)...
La FDA aprueba una nueva opción de tratamiento con buprenorfina para el trastorno por consumo de opioides
Para publicación inmediata: 24 de mayo del 2023
Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) aprobó la inyección subcutánea (para uso por debajo de la piel) de Brixadi...
Chamada Anual da Cúpula de Deflexão do PTACC para Apresentadores Internacionais
Estão sendo aceitas propostas para a Cúpula Nacional de Deflexão e Desvio Pré-Prisão de 2023 do Police, Treatment, and Community Collaborative (PTACC).
Todas as submissões devem ser enviadas até 5 de maio de 2023 às 2:00 EDT para serem...
National Substance Use and Mental Health Services Survey (N-SUMHSS), 2021: Dados sobre o uso de substâncias e instalações de tratamento de saúde mental
O N-SUMHSS é uma pesquisa anual voluntária de todas as instalações de uso de substâncias ativas e saúde mental nos Estados Unidos, seus territórios e DC. O relatório anual apresenta resultados sobre o perfil geral do uso de substâncias e...
Outpatient Alcohol Withdrawal Management: A Tool for Global Practice Settings
Resilience in Leadership: Key Behaviors for Self-Care and Caring for Others
ICUDDR November 2022 Newsletter
We are pleased to present our November 2022 newsletter, please enjoy the articles and share at your leisure. Thank you!
The Substance Use Professional’s Guide to Addressing Medical Cannabis in Substance Use Treatment Settings
New Training for Medical Providers: Integrating Addiction Medicine With Treatment Courts
NADCP is partnering with the American Society of Addiction Medicine (ASAM) to offer a new training for medical providers working with participants in drug treatment courts. This training will help medical providers learn how to successfully...
NIDA Releases Its 2022-2026 Strategic Plan
This week, NIDA releases its strategic plan for FY 2022-2026. Strategic planning is a process all NIH Institutes perform every five years, to take stock of the current state of research and set priorities that are ambitious but achievable...
Compartilhe o conhecimento: membros ISSUP podem postar no Compartilhamento de Conhecimento - Entre ou torne-se um membro